My interest is in dysregulated signal transduction associated with cancer. Our work is largely focused on the IKK/NF-kappaB pathway, which occurs in a variety of cancers. We were the first to show that NF-kB is activated downstream of oncogenic Ras mutations and that blocking NF-kB strongly reduces the oncogenic nature of Ras. We are currently studying an IKK-related kinase, TBK1, and its oncogenic role downstream of Ras mutations, focused on pancreatic cancer. We have found that EZH2 interacts with NF-kappaB to drive cancer-associated phenotypes in breast cancer. We collaborate with numerous investigators related to NF-kappaB signaling in cancer.